Unoprostone Knowpia

Unoprostone
Clinical data
Trade names	Rescula
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Topical (eye drops)
ATC code	S01EE02 (WHO) ;
Legal status
Legal status	US: Discontinued;
Pharmacokinetic data
Elimination half-life	14 min
Excretion	Renal
Identifiers
	IUPAC name (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl); cyclopentyl]hept-5-enoic acid;
CAS Number	120373-36-6 120373-24-2 (isopropyl ester);
PubChem CID	5311236;
DrugBank	DB06826 ;
ChemSpider	4470755 ;
UNII	6X4F561V3W;
KEGG	D08661 ;
ChEMBL	ChEMBL1201407 ;
CompTox Dashboard (EPA)	DTXSID80905120 ;
ECHA InfoCard	100.227.145
Chemical and physical data
Formula	C22H38O5
Molar mass	382.541 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCC(=O)CCCCCCC;
	InChI InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1 ; Key:TVHAZVBUYQMHBC-SNHXEXRGSA-N ;
	(what is this?) (verify)

Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.^[1]^[2]

It was approved by the Food and Drug Administration in 2000.^[3]

In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.^[4]

In 2015, the drug was discontinued in the U.S.^{[citation needed]}

References edit

^ Micromedex Detailed Consumer Information
^ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. 8. Auckland, N.Z.: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
^ "Drug Approval Package". Food and Drug Administration.
^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.